OmicsDiscoveries

Executive Summary

OmicsDiscoveries is a German biotechnology company founded in 2017 that leverages artificial intelligence and multi-omics data to simplify and accelerate genetic analysis for rare disease diagnosis. Its flagship platform, RNAvision, transforms complex RNA sequencing data into interpretable clinical reports, enabling physicians to identify causative variants more efficiently. The platform is built on peer-reviewed statistical methods and software developed by the founding team, providing a strong scientific foundation. Despite being private with undisclosed funding, the company has gained visibility through listings on biotech databases and is positioned to address a significant unmet need in rare disease diagnostics. OmicsDiscoveries operates at the intersection of proteomics, genomics, and AI, offering a differentiated approach that could reduce diagnostic odysseys and improve patient outcomes. The company's core strength lies in its ability to integrate multi-omics data with machine learning, moving beyond standard genomics to incorporate transcriptomic insights. This holistic view increases diagnostic yield for rare diseases where traditional genetic testing often fails. While OmicsDiscoveries is currently in a pre-revenue stage with no disclosed commercial product or regulatory approvals, its technology has potential for broad clinical adoption. The near-term focus will likely be on validating the platform through clinical studies, securing partnerships with diagnostic laboratories, and obtaining regulatory certifications such as CE-IVD for the European market. With a dedicated team and a clear value proposition, OmicsDiscoveries is well-positioned to capture market share in the growing rare disease diagnostic space.

Upcoming Catalysts (preview)

• Q3 2026Publication of clinical validation study for RNAvision platform60% success
• Q4 2026Strategic partnership with a major European diagnostic laboratory50% success
• TBDAchievement of CE-IVD certification for RNAvision40% success